OP Asset Management Ltd Purchases Shares of 334,412 Niagen Bioscience, Inc. $NAGE

OP Asset Management Ltd acquired a new stake in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 334,412 shares of the company’s stock, valued at approximately $1,475,000.

Several other large investors have also modified their holdings of NAGE. Silverberg Bernstein Capital Management LLC boosted its position in shares of Niagen Bioscience by 5.3% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 138,102 shares of the company’s stock worth $609,000 after acquiring an additional 6,940 shares during the last quarter. Corient Private Wealth LLC acquired a new position in Niagen Bioscience during the fourth quarter worth approximately $200,000. Invesco Ltd. raised its stake in Niagen Bioscience by 28.5% during the fourth quarter. Invesco Ltd. now owns 43,641 shares of the company’s stock worth $278,000 after purchasing an additional 9,688 shares during the period. SummitTX Capital L.P. purchased a new position in Niagen Bioscience during the fourth quarter worth approximately $79,000. Finally, Tudor Investment Corp ET AL purchased a new position in Niagen Bioscience during the fourth quarter worth approximately $360,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on NAGE shares. Canaccord Genuity Group lowered their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wall Street Zen lowered Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. HC Wainwright reduced their target price on Niagen Bioscience from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.50.

Niagen Bioscience Stock Performance

NASDAQ NAGE opened at $3.30 on Tuesday. The firm has a market capitalization of $262.81 million, a price-to-earnings ratio of 15.71 and a beta of 2.08. Niagen Bioscience, Inc. has a one year low of $3.27 and a one year high of $14.69. The company’s 50 day moving average price is $3.91 and its 200 day moving average price is $4.94.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. The company had revenue of $31.47 million during the quarter. Sell-side analysts forecast that Niagen Bioscience, Inc. will post 0.22 EPS for the current fiscal year.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.